rise in US generics to US$ 253mn (vs. estimated US$ 263mn). ROW/ARV sales jumped 25%/23%,whereasEUsalesgrewby9%.EBITDAmarginexpandedby~280bpsto23.5%(vs. estimated23.8%).CorePAT(adjustedforforexgainofRs45mn)wasRs5.59bn(+38%yoy),...